#United States #Cancer Research #Lexington #Curis #emavusertib

Curis Reports Third Quarter 2026 Results

Curis, Inc., a prominent player in the biotechnology sector, has officially announced its financial and operational updates for the third quarter of 2026. The company's primary focus is on the promising development of emavusertib (CA-4948), an oral small molecule that inhibits both IRAK4 and FLT3, which are critical targets in oncological therapies.

Operational Highlights

Curis is advancing with two pivotal studies: the TakeAim CLL and the TakeAim Lymphoma trials. According to James Dentzer, the Chief Executive Officer, there is palpable excitement amongst the clinical community and patients alike, as emavusertib promises to potentially revolutionize treatment protocols for both chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL).

TakeAim CLL Study

The TakeAim CLL study is an open-label Phase 2 clinical trial investigating the efficacy of emavusertib combined with zanubrutinib in CLL patients. To qualify for this study, participants must have undergone at least 12 months of treatment with zanubrutinib, achieved either a partial response or a partial response with an increase in lymphocyte counts, and exhibit measurable residual disease per the clonoSEQ assay metrics. As of now, 12 patients have been successfully enrolled, with preliminary results anticipated to be disclosed in December 2026.

TakeAim Lymphoma Study

Similarly, the TakeAim Lymphoma study focuses on emavusertib in combination with ibrutinib for relapsed/refractory PCNSL cases. Last year, Curis shared insightful initial clinical data with the U.S. FDA and the European Medicines Agency, which could lead to accelerated approval pathways in this challenging setting. In July 2026, updated results indicated that 100% of therapy-naïve patients showed clinical benefit, with overall response rates markedly higher in previously untreated subjects compared to those with prior treatment history.

Financial Overview

For the third quarter of 2026, Curis reported a net loss of $8.1 million, translating to $1.94 per share, which reflects a slight increase compared to the same quarter in 2025 when the loss was $7.7 million. Notably, the company did not generate revenue during the quarter due to the earlier sale of royalty rights for one of its previous products. However, an essential public offering occurred in August 2026, along with a private placement in October that extended its financial runway into 2027. Curis ended the quarter with $5.0 million in cash and cash equivalents.

Research & Development Expenses

Curis has recorded research and development expenditures totaling $5.6 million in Q3 2026, which represents a decrease from $6.4 million in the same quarter a year prior. This downtrend is primarily attributed to reduced employee-related expenses despite an uptick in clinical trial costs. Meanwhile, general and administrative costs also fell slightly to $3.2 million, down from $3.7 million in Q3 2025.

Additional Insights

Looking forward, Curis aims to leverage its existing financial framework alongside new investments to continue the development of emavusertib. Their primary focus remains on achieving superior treatment outcomes that could particularly benefit patients with challenging forms of cancer. This drive for innovation, accountability, and effective resource utilization underpins Curis's commitment to making meaningful contributions to cancer therapy.

As the clinical landscape evolves, Curis is determined to keep stakeholders informed through its scheduled conference call and webcast, where management will delve deeper into the business update and financial assertions made thus far.

For more detailed information about Curis, its research initiatives, or to participate in the upcoming conference call, potential investors and interested parties are encouraged to visit their official website.

Curis, Inc. continues to embody the essence of hope in the biotechnology field, striving to transform and enhance the lives of those affected by serious diseases through their innovative research and development practices.